“Primary” and “secondary” muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes

por Pietzak, Eugene J., Al-Ahmadie, Hikmat, Walasek, Aleksandra, Bajorin, Dean F., Rosenberg, Jonathan E., Bochner, Bernard H., Solit, David B., Iyer, Gopa
Publicado 2019

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

por Chandarlapaty, Sarat, Scaltriti, Maurizio, Angelini, Pierdavide, Ye, Qing, Guzman, Marta, Hudis, Clifford A., Norton, Larry, Solit, David B., Arribas, Joaquin, Baselga, Jose, Rosen, Neal
Publicado 2009

Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases

por Shady, Waleed, Petre, Elena N., Vakiani, Efsevia, Ziv, Etay, Gonen, Mithat, Brown, Karen T., Kemeny, Nancy E., Solomon, Stephen B., Solit, David B., Sofocleous, Constantinos T.
Publicado 2017

PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases

por Ziv, Etay, Bergen, Michael, Yarmohammadi, Hooman, Boas, F. Ed, Petre, E. Nadia, Sofocleous, Constantinos T., Yaeger, Rona, Solit, David B., Solomon, Stephen B., Erinjeri, Joseph P.
Publicado 2017

Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors

por Regales, Lucia, Balak, Marissa N., Gong, Yixuan, Politi, Katerina, Sawai, Ayana, Le, Carl, Koutcher, Jason A., Solit, David B., Rosen, Neal, Zakowski, Maureen F., Pao, William
Publicado 2007

3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets

por Gao, Jianjiong, Chang, Matthew T., Johnsen, Hannah C., Gao, Sizhi Paul, Sylvester, Brooke E., Sumer, Selcuk Onur, Zhang, Hongxin, Solit, David B., Taylor, Barry S., Schultz, Nikolaus, Sander, Chris
Publicado 2017

Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors

por Aregbe, Abdulateef O., Sherer, Eric A., Egorin, Merrill J., Scher, Howard I., Solit, David B., Ramanathan, Ramesh K., Ramalingam, Suresh, Belani, Chandra P., Ivy, Percy S., Bies, Robert R.
Publicado 2012

Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells

por Korkut, Anil, Wang, Weiqing, Demir, Emek, Aksoy, Bülent Arman, Jing, Xiaohong, Molinelli, Evan J, Babur, Özgün, Bemis, Debra L, Onur Sumer, Selcuk, Solit, David B, Pratilas, Christine A, Sander, Chris
Publicado 2015

Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity

por Chang, Matthew T., Asthana, Saurabh, Gao, Sizhi Paul, Lee, Byron H., Chapman, Jocelyn S., Kandoth, Cyriac, Gao, JianJiong, Socci, Nicholas D., Solit, David B., Olshen, Adam B., Schultz, Nikolaus, Taylor, Barry S.
Publicado 2015

Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma

por Vakiani, Efsevia, Shah, Ronak H., Berger, Michael F., Makohon-Moore, Alvin P., Reiter, Johannes G., Ostrovnaya, Irina, Attiyeh, Marc A., Cercek, Andrea, Shia, Jinru, Iacobuzio-Donahue, Christine A., Solit, David B., Weiser, Martin R.
Publicado 2017

Perturbation Biology: Inferring Signaling Networks in Cellular Systems

por Molinelli, Evan J., Korkut, Anil, Wang, Weiqing, Miller, Martin L., Gauthier, Nicholas P., Jing, Xiaohong, Kaushik, Poorvi, He, Qin, Mills, Gordon, Solit, David B., Pratilas, Christine A., Weigt, Martin, Braunstein, Alfredo, Pagnani, Andrea, Zecchina, Riccardo, Sander, Chris
Publicado 2013

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway

por Smith, Alison E., Ferraro, Emanuela, Safonov, Anton, Morales, Cristina Bernado, Lahuerta, Enrique J. Arenas, Li, Qing, Kulick, Amanda, Ross, Dara, Solit, David B., de Stanchina, Elisa, Reis-Filho, Jorge, Rosen, Neal, Arribas, Joaquín, Razavi, Pedram, Chandarlapaty, Sarat
Publicado 2021

Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building

por Sherer, Eric A., Sale, Mark E., Pollock, Bruce G., Belani, Chandra P., Egorin, Merrill J., Ivy, Percy S., Lieberman, Jeffrey A., Manuck, Stephen B., Marder, Stephen R., Muldoon, Matthew F., Scher, Howard I., Solit, David B., Bies, Robert R.
Publicado 2012

KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer

por Qiu, Hong, Makarov, Vladimir, Bolzenius, Jennifer K., Halstead, Angela, Parker, Yvonne, Wang, Allen, Iyer, Gopakumar V., Wise, Hannah, Kim, Daniel, Thayaparan, Varna, Lindner, Daniel J., Haber, Georges-Pascal, Ting, Angela H., Ren, Bing, Chan, Timothy A., Arora, Vivek, Solit, David B., Lee, Byron H.
Publicado 2023

PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer

por Nixon, Mellissa J., Formisano, Luigi, Mayer, Ingrid A., Estrada, M. Valeria, González-Ericsson, Paula I., Isakoff, Steven J., Forero-Torres, Andrés, Won, Helen, Sanders, Melinda E., Solit, David B., Berger, Michael F., Cantley, Lewis C., Winer, Eric P., Arteaga, Carlos L., Balko, Justin M.
Publicado 2019

Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion

por Straussman, Ravid, Morikawa, Teppei, Shee, Kevin, Barzily-Rokni, Michal, Qian, Zhi Rong, Du, Jinyan, Davis, Ashli, Mongare, Margaret M., Gould, Joshua, Frederick, Dennie T., Cooper, Zachary A., Chapman, Paul B., Solit, David B., Ribas, Antoni, Lo, Roger S., Flaherty, Keith T., Ogino, Shuji, Wargo, Jennifer A., Golub, Todd R.
Publicado 2012

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

por Batalini, Felipe, Gulhan, Doga C., Mao, Victor, Tran, Antuan, Polak, Madeline, Xiong, Niya, Tayob, Nabihah, Tung, Nadine M., Winer, Eric P., Mayer, Erica L., Knappskog, Stian, Lønning, Per E., Matulonis, Ursula A., Konstantinopoulos, Panagiotis A., Solit, David B., Won, Helen, Eikesdal, Hans P., Park, Peter J., Wulf, Gerburg M.
Publicado 2022

Genome doubling shapes the evolution and prognosis of advanced cancers

por Bielski, Craig M., Zehir, Ahmet, Penson, Alexander V., Donoghue, Mark T.A., Chatila, Walid, Armenia, Joshua, Chang, Matthew T., Schram, Alison M., Jonsson, Philip, Bandlamudi, Chaitanya, Razavi, Pedram, Iyer, Gopa, Robson, Mark E., Stadler, Zsofia K., Schultz, Nikolaus, Baselga, Jose, Solit, David B., Hyman, David M., Berger, Michael F., Taylor, Barry S.
Publicado 2018

Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma

por Teo, Min Yuen, Al-Ahmadie, Hikmat, Seier, Kenneth, Tully, Christopher, Regazzi, Ashley M., Pietzak, Eugene, Solit, David B., Tickoo, Satish, Reuter, Victor, Cha, Eugene K., Herr, Harry, Donahue, Timothy, Donat, Sherri M., Dalbagni, Guido, Bochner, Bernard H., Funt, Samuel, Iyer, Gopakumar V., Bajorin, Dean F., Ostrovnaya, Irina, Rosenberg, Jonathan E.
Publicado 2021

AKT mutant allele-specific activation dictates pharmacologic sensitivities

por Shrestha Bhattarai, Tripti, Shamu, Tambudzai, Gorelick, Alexander N., Chang, Matthew T., Chakravarty, Debyani, Gavrila, Elena I., Donoghue, Mark T. A., Gao, JianJong, Patel, Swati, Gao, Sizhi Paul, Reynolds, Margaret H., Phillips, Sarah M., Soumerai, Tara, Abida, Wassim, Hyman, David M., Schram, Alison M., Solit, David B., Smyth, Lillian M., Taylor, Barry S.
Publicado 2022